Esperion Therapeutics Inc. (ESPR) Cut to Hold at Zacks Investment Research
Esperion Therapeutics Inc. (NASDAQ:ESPR) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a report released on Monday.
According to Zacks, “Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. “
Several other equities analysts have also recently weighed in on ESPR. Credit Suisse Group AG cut Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price target for the company from $23.00 to $10.00 in a research report on Wednesday, June 29th. JPMorgan Chase & Co. cut Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $50.00 to $15.00 in a research report on Wednesday, June 29th. Royal Bank Of Canada cut Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $30.00 to $15.00 in a research report on Wednesday, June 29th. Lake Street Capital reduced their price target on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, June 29th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $22.00 price target (down from $36.00) on shares of Esperion Therapeutics in a research report on Wednesday, June 29th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $26.36.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/esperion-therapeutics-inc-espr-cut-to-hold-at-zacks-investment-research.html
Esperion Therapeutics (NASDAQ:ESPR) traded up 1.58% during trading on Monday, reaching $12.24. The company’s stock had a trading volume of 428,358 shares. The stock has a 50-day moving average price of $12.34 and a 200 day moving average price of $13.96. Esperion Therapeutics has a 52-week low of $9.58 and a 52-week high of $30.41. The company’s market cap is $276.01 million.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. During the same period in the previous year, the firm earned ($0.55) earnings per share. On average, analysts expect that Esperion Therapeutics will post ($3.37) EPS for the current year.
Several large investors have recently added to or reduced their stakes in ESPR. Quantitative Investment Management LLC bought a new stake in Esperion Therapeutics during the second quarter worth $111,000. Advisor Group Inc. acquired a new position in shares of Esperion Therapeutics during the second quarter worth about $140,000. Stifel Financial Corp increased its position in shares of Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares in the last quarter. Rhumbline Advisers increased its position in shares of Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in shares of Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 238 shares in the last quarter. 65.23% of the stock is owned by institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.